Moderna (MRNA) is in a precarious position, the company bet big on mRNA to develop shots to treat or prevent different diseases, but, after securing riches from its Covid shot, the company has failed to diversify its pipeline, Jared Hopkins and Peter Loftus of The Wall Street Journal reports. This has become increasingly detrimental for the company as the Trump administration casts a critical eye on the technology and seeks to reshape the regulation, recommendations, and development of vaccines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Cautious Outlook on Moderna: Sell Rating Amid Financial and Legal Challenges
- VOO ETF News, 6/2/2025
- Morning Movers: Trump to bump steel tariffs, pharma companies announce deals
- Cautious Outlook on Moderna’s mNexspike Vaccine Amid Restrictive FDA Approval and Regulatory Changes
- Moderna announces FDA approved mNEXSPIKE, new vaccine against COVID-19